Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Condition:   Primary Immune Deficiency Intervention:   Biological: Newnorm Sponsor:   Octapharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials